Viking Therapeutics, Inc.VKTXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
49.54%
↑ 304% above average
Average (39q)
12.26%
Historical baseline
Range
High:71.57%
Low:-41.69%
CAGR
+1.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 49.54% |
| Q2 2025 | 45.33% |
| Q1 2025 | 33.58% |
| Q4 2024 | 36.00% |
| Q3 2024 | -4.14% |
| Q2 2024 | -1.39% |
| Q1 2024 | 17.56% |
| Q4 2023 | 11.55% |
| Q3 2023 | 32.06% |
| Q2 2023 | 26.43% |
| Q1 2023 | -31.96% |
| Q4 2022 | 35.28% |
| Q3 2022 | -11.69% |
| Q2 2022 | 7.86% |
| Q1 2022 | 27.50% |
| Q4 2021 | -8.78% |
| Q3 2021 | -15.69% |
| Q2 2021 | 11.00% |
| Q1 2021 | 27.49% |
| Q4 2020 | 27.15% |
| Q3 2020 | -8.53% |
| Q2 2020 | -2.59% |
| Q1 2020 | 23.81% |
| Q4 2019 | 22.20% |
| Q3 2019 | -28.01% |
| Q2 2019 | 63.10% |
| Q1 2019 | -11.65% |
| Q4 2018 | -10.52% |
| Q3 2018 | 8.93% |
| Q2 2018 | 71.57% |
| Q1 2018 | 0.33% |
| Q4 2017 | -12.46% |
| Q3 2017 | -6.75% |
| Q2 2017 | 5.31% |
| Q1 2017 | 33.27% |
| Q4 2016 | 25.78% |
| Q3 2016 | -11.23% |
| Q2 2016 | 26.31% |
| Q1 2016 | -41.69% |
| Q4 2015 | 28.39% |